| Name | Title | Contact Details |
|---|
Biosign Technologies Inc. engages in the development, manufacture, and sale of medical devices and information systems. The company provides cloud based systems for non-invasive monitoring of common health risks associated with blood pressure, life style, and medication. Its analysis and reporting tools give patients and their healthcare team access to real-time health information for treatment planning, evaluation, and management. The company offers UFIT, an automated wrist sphygmography system with computer controls that measures various signs, including blood pressure, mean arterial pressure, pulse rate, and pulse rate variability from a single digital signal acquired passively with an inflatable cuff at the wrist. It also provides Healthanywhere, a software-based, remote patient monitoring application that runs on Windows PC and Blackberry platforms. Healthanywhere solution provides for the continuum of care from wellness promotion to self-managed care, including monitoring of chronic diseases, such as congestive heart failure, hypertension, diabetes, asthma, and obesity. Biosign Technologies Inc. was incorporated in 2004 and is headquartered in Thornhill, Canada.
New England Institutional Review Board NEIRB is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
uBiome is the leading microbial genomics company. We are pioneering a new era of microbiome-based precision medicine. We allow doctors, patients, and citizen scientists to learn about the human microbiome with unprecedented accuracy and speed.
Sirona Dental Systems, Inc. (Sirona) is a manufacturer of dental equipment. Sirona focuses on developing innovative systems and solutions for dentists globally.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.